Inhibition of platelet prostaglandin synthetase by oral aspirin
- J Clin Invest. 1978 Feb;61(2):314-9. doi: 10.1172/JCI108941.
Aspirin inhibits platelet function by permanently acetylating the cyclooxygenase that forms prostaglandins. We determined the sensitivity of platelets to aspirin in normal subjects by measuring [3H-acetyl]aspirin-susceptible cyclooxygenase in washed platelets obtained at various times after aspirin ingestion. A single 325-mg aspirin dose inactivated 89% of platelet cyclooxygenase. The inhibition persisted for 2 days suggesting that oral aspirin also inactivated megakaryocyte cyclooxygenase. Thereafter, active enzyme returned with a time-course reflecting platelet turnover (life-span 8.2+/-2 days). Single doses of 20-650 mg aspirin resulted in 34- greater than 95% inhibition after 24 h. Daily doses of 20-325 mg aspirin for brief periods produced 61- greater than 95% inactivation when measured 24 h after cessation of the drug. Platelet cyclooxygenase is more sensitive to inactivation by aspirin than enzyme in sheep seminal vesicles.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Autophagy; NF-κB; p38 MAPK; Environmental Pollutants; Mitophagy; Caspase; Apoptosis; Virus Protease; COXResearch Areas: Neurological Disease; Metabolic Disease; Inflammation/Immunology; Infection; Cardiovascular Disease; Cancer
-
Research Areas: Metabolic Disease; Inflammation/Immunology; Infection; Cardiovascular Disease; Cancer
-
Research Areas: Metabolic Disease; Inflammation/Immunology; Infection; Cardiovascular Disease; Cancer
-
target: Autophagy; NF-κB; p38 MAPK; Mitophagy; Caspase; Apoptosis; Virus Protease; Isotope-Labeled Compounds; COXResearch Areas: Metabolic Disease; Inflammation/Immunology; Infection; Cardiovascular Disease; Cancer